Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment
French firm Servier Pharmaceutical plc. and IDEAYA Biosciences Inc. (NASDAQ: IDYA) announced an exclusive licensing...
IDEAYA Biosciences
Hengrui Pharmaceuticals Receives NMPA Clearance for Phase II Trial of SHR-4849, SHR-8068, and Adebrelimab in Advanced Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received regulatory clearance...
Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...
Biocytogen’s First-in-Class B7H3/PTK7 Bispecific ADC Option Exercised by IDEAYA Biosciences
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced that its...
Biocytogen Strikes Licensing Deal with IDEAYA for Potential First-in-Class BsADC Program
China-based Biocytogen (HKG: 2315) has entered into an option and licensing agreement with US-based IDEAYA...
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...